Stifel analyst Rick Wise raised the firm’s price target on Intuitive Surgical (ISRG) to $525 from $475 and keeps a Buy rating on the shares. The company delivered “strong” Q3 results and the two most critical quarterly line-items – DV5 placements and procedure growth – both exceeded expectations, the analyst tells investors in a post-earnings note. Seven months following the U.S. da Vinci 5 approval, Intuitive is already generating meaningful post-launch growth momentum and early DV5 uptake is tracking well-ahead of the fourth generation system launch, with “strong growth encouragingly suggesting potential acceleration ahead in 2025,” the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ISRG:
- Intuitive Surgical price target raised to $535 from $518 at BTIG
- Intuitive Surgical price target raised to $565 from $503 at Baird
- Intuitive Surgical price target raised to $538 from $495 at Piper Sandler
- Closing Bell Movers: Netflix gains 5% as Q3 earnings, Q4 guidance top estimates
- ISRG Earnings: Intuitive Surgical’s Financial Results Beat Estimates